Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Esophageal Squamous Cell Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Vomiting 1Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Nausea 1Lung Neoplasms 1Klatskin Tumor 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 2tislelizumab 1pembrolizumab 1enfortumab vedotin 1cabozantinib 1VMBP protocol 1Pemetrexed 1Nivolumab 1Neoadjuvant Therapy 1Gemcitabine 1Docetaxel 1Carboplatin 1Administration, Intravesical 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Urologic Neoplasms × Neoadjuvant Therapy × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔